Latest News about IOVA
Recent news which mentions IOVA
From Motley Fool
 
   Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
   
  May 20, 2025
  Tickers 
   IOVA
  
  
  From Motley Fool
 From Motley Fool
 From Benzinga
 Tickers 
   IOVA
  
  
  From Motley Fool
 
   3 Monster Stocks in the Making
   
  
  
  May 11, 2025
  From Motley Fool
 From Benzinga
 
   Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
   
  
  
  May 09, 2025
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   Earnings Scheduled For May 8, 2025
   
  
  
  May 08, 2025
  From Benzinga
 
   My 3 Favorite Stocks to Buy Right Now
   
  
  
  May 06, 2025
  From Motley Fool
 
   2 Beaten-Down Stocks With Incredible Upside Potential
   
  
  
  April 30, 2025
  From Motley Fool
 
   Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
   
  April 23, 2025
  Tickers 
   IOVA
  
  
  From Motley Fool
 Tickers 
   IOVA
  
  
  From Motley Fool
 From Motley Fool
 
   Top 3 Health Care Stocks That Are Set To Fly This Month
   
  
  
  March 26, 2025
  From Benzinga
 Tickers 
   IOVA
  
  
  From Motley Fool
 From Motley Fool
 
   Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
   
  March 12, 2025
  Tickers 
   IOVA
  
  
  From Motley Fool
 
   Earnings Scheduled For February 27, 2025
   
  
  
  February 27, 2025
  From Benzinga
 
   My 3 Favorite Stocks to Buy Right Now
   
  
  
  February 20, 2025
  From Motley Fool
 
   Iovance Biotherapeutics Shares Fell Today: What's Going On?
   
  
  
  February 10, 2025
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
